Nivolumab for Prostate Cancer
Study Summary
This trial is testing a new safety drug in two phases. First, a small group of people will test it to make sure it's safe. If it is, then a larger group of people will use it.
- Metastatic Castration Resistant Prostate Cancer
Eligibility Criteria
Inclusion Criteria
You will be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 3 trial • 541 Patients • NCT02041533Awards & Highlights
Trial Design
Find a site
Who is running the clinical trial?
Media Library
Frequently Asked Questions
What is the total enrollment capacity for this medical experiment?
"Affirmative. Clinicaltrials.gov details indicate that this trial was launched on August 25 2020 and is currently seeking volunteers. 36 participants need to be enrolled at a single clinical site."
Are there any openings left for this clinical trial?
"Affirmative. As confirmed by clinicaltrials.gov, the medical study is still recruiting participants as of April 21st 2022; it was first advertised on August 25th 2020. The research project demands 36 volunteers from 1 site to partake in the trial."
Is this research unprecedented in its approach?
"Research surrounding Nivolumab began in 2012, when Ono Pharmaceutical Co. Ltd sponsored its initial study involving 659 patients. This led to the drug receiving Phase 1 and 2 approval, sparking a wave of clinical trials around the world with 723 active studies occurring across 2357 cities and 49 countries today."
In what medical scenarios is Nivolumab typically prescribed?
"Nivolumab has been found to have positive effects in treating malignant tumours, unresectable melanoma, and squamous cell carcinomas."
Can you please provide an overview of the prior research on Nivolumab?
"Currently, 723 trials are actively researching Nivolumab with 83 Phase 3 studies. The medication is being investigated in 40342 different areas of the globe, including Basel, BE."
What is the aim of this experiment?
"The primary objective of this medical trial, anticipated to last 30 months, is the assessment of nivolumab's safety when combined with Radium-223 in patients with metastatic castrate resistant prostate cancer. Additionally, researchers will evaluate radiographic progression-free survival according to PCWG3 criteria and PSA progression free survival using Prostate Cancer Working Group 3 (PCWG3). Lastly, there will be a correlation analysis between bone metabolism markers and clinical response."